Rein Therapeutics, Inc. 8-K

What Happened
Rein Therapeutics, Inc. (RNTX) announced it entered into securities purchase agreements on February 24 and 27, 2026, selling unsecured promissory notes in a private placement. The notes have an aggregate original principal amount of $2,875,000 but were sold for an aggregate purchase price of $2,300,000 due to a 20% original issue discount. The notes mature on the earlier of (a) the closing of the company’s next financing that raises at least $10,000,000 (exclusive of these note proceeds) or (b) June 30, 2026. The notes bear no interest other than the 20% original issue discount and the obligations are unsecured.

Key Details

• Issuance dates: February 24 and 27, 2026; three institutional investors participated.
• Economics: $2,875,000 original principal; $2,300,000 cash proceeds (20% original issue discount).
• Maturity: Earlier of next qualifying financing of ≥ $10,000,000 or June 30, 2026.
• Terms: No periodic interest (other than OID); unsecured; sold in a private placement under securities purchase agreements.

Why It Matters
This filing documents a short-term financing move that increases the company’s cash by $2.3M and creates a direct financial obligation of $2.875M in principal (before accounting for the original issue discount). For investors, it signals the company is using bridge-style debt to fund operations until a larger financing (≥ $10M) or the June 30, 2026 maturity. Monitor Rein’s cash runway and any forthcoming financing terms, since the notes accelerate at a qualifying financing or reach maturity in mid-2026.